eファーマシーの重要動向、地域別分析、市場予測　2022-2027年

• Juniper Researchの競合スコアボード：主要15社の特性と能力評価
  • 1mg
  • Amazon Pharmacy
  • Apollo Pharmacy
  • CVS Health
  • DocMorris
  • Express Scripts
  • Giant Eagle Pharmacy
  • Kroger
  • Lloyds Pharmacy
  • Netmeds
  • Optum
  • Rowlands Pharmacy
  • Walgreens Boots Alliance
  • Walmart
  • Well Pharmacy

当レポートは下記疑問への回答につながる情報を提供しています。

1. 主要市場の動向がeファーマシーへどのような影響を与えるか？
2. eファーマシーはOTCと処方箋医薬品とどのような違いがあるか？
3. eファーマシー市場における主要ベンダは？
4. eファーマシーにとって成長阻害要因となる限界は？
5. eファーマシーがもっとも成功する地域は？

Report Overview

Juniper Research’s ePharmacy report provides a detailed evaluation of the market, including the adoption of ePharmacy within both developing and established markets. In addition, this report covers market opportunities; providing strategic insights into the technologies and key drivers that are pushing the space forward, and the role of 15 leading ePharmacy vendors across the market.

The research suite also contains a detailed dataset; providing forecasts for 60 countries across a number of different metrics, including the number of ePharmacy users, number of ePharmacy transactions, number of OTC (Over the Counter) and prescription transactions through ePharmacy and total ePharmacy revenue.

This research suite comprises of:

• Strategy & Forecasts (PDF)
• 5-year Market Sizing & Forecast Spreadsheet (Excel)
• 12 Months Access to harvest Online Data Platform

KEY FEATURES

• Market Dynamics: A strategic analysis of the major drivers, challenges, and innovations shaping the adoption and development of ePharmacy technologies, including the following:
  • COVID-19 impact on the ePharmacy market
  • Future strategic direction and market outlook for ePharmacy
  • Key issues ePharmacy vendors must be aware of surrounding legislation and data sharing
• Regional Analysis: A regional-level analysis of 16 countries, spanning 8 key regions; covering the current deployment level and future outlook of ePharmacy in each market.
• Key Takeaways & Strategic Recommendations: Analysis of key development opportunities within ePharmacies, accompanied by key strategic recommendations for stakeholders.
• Benchmark Industry Forecasts: Includes forecasts for total number of ePharmacy users, total annual spend on ePharmacy, total fee revenue from ePharmacy, total transaction value from ePharmacy. Total number of transactions and revenue split by OTC and prescription medication. This data is split by our 8 key forecast regions and 60 countries:
  • North America:
    • Canada, US
  • Latin America:
    • Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Peru, Uruguay
  • West Europe:
    • Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, UK
  • Central & East Europe:
    • Croatia, Czech Republic, Hungary, Poland, Romania, Russia, Turkey, Ukraine
  • Far East & China:
    • China, Hong Kong, Japan, South Korea
  • Indian Subcontinent:
    • Bangladesh, India, Nepal, Pakistan
  • Rest of Asia Pacific:
    • Australia, Indonesia, Malaysia, New Zealand, Philippines, Singapore, Thailand, Vietnam
  • Africa & Middle East:
    • Algeria, Egypt, Israel, Kenya, Kuwait, Nigeria, Qatar, Saudi Arabia, South Africa, United Arab Emirates
• Juniper Research Competitor Leaderboard: Key player capability and capacity assessment for 15 ePharmacy vendors:
  • 1mg
  • Amazon Pharmacy
  • Apollo Pharmacy
  • CVS Health
  • DocMorris
  • Express Scripts
  • Giant Eagle Pharmacy
  • Kroger
  • Lloyds Pharmacy
  • Netmeds
  • Optum
  • Rowlands Pharmacy
  • Walgreens Boots Alliance
  • Walmart
  • Well Pharmacy

KEY QUESTIONS ANSWERED

1. How will key market trends affect ePharmacy?
2. How will ePharmacy differ for over-the-counter and prescription medication?
3. Who are the leading vendors in the ePharmacy market?
4. What limitations are holding back ePharmacy?
5. What regions will ePharmacy be most successful in?

COMPANIES REFERENCED

Included in the Juniper Research Competitor Leaderboard: 1mg, Amazon Pharmacy, Apollo Pharmacy, CVS Health, DocMorris, Express Scripts, Giant Eagle, Lloyds Pharmacy, Netmeds, Optum, Rowlands Pharmacy, The Kroger, Walgreens Boots Alliance, Walmart, Well Pharmacy.

Mentioned: Accredo, Adipositas Care, Adobe, Aetna, Bajaj Allianz, Bakers, Berkshire Hathaway, Blue Cross Blue Shield, Braze, CareCentrix, CareContinum, CareZone, Chefaa, City Market Food and Pharmacy, Copps, CuraScriptSD, Deliveroo, Ecrebo, Epic, Evicore Healthcare, Famhealth, FredMeyer, Freedom Fertility Pharmacy, Frys, HasHealth, Haven, HDFC, Horizon, ICICI Bank, Inside Rx, JPMorgan Chase, KiviHealth, Lazada Philippines, Lyf, Mamajan Imaging, Max Bupa, MedAvail, Medbase, Mesmerize, Microsoft, MyMatrixx, NCotably, Novo Nordisk, Omnicell, Onofre, Patanjali, PathCare, PAYBACK, PillPack, Practio, Prime Therapeutics, Raia Drogasil SA, SBI, Shopee Philippines, Signify Health, Target Pharmacies, Tata Digital, TeleClinic, Thyrocare, Verizon, Willons, Yodawy, ZEE5, Zur Rose Group.

DATA & INTERACTIVE FORECAST

Juniper Research’s ePharmacy forecast suite includes:

• Prescription Medication
• Over-the-Counter Medication

Metrics including total number of transactions completed through ePharmacy, total annual spend on ePharmacy, total revenue through ePharmacy transactions, total revenue through ePharmacy fees, split by OTC and prescription medication.

Geographical splits: 60 countries
Number of tables: Over 31 tables
Number of datapoints: Over 23,500 datapoints

harvest: Our online data platform, harvest, contains the very latest market data and is updated throughout the year. This is a fully featured platform enabling clients to better understand key data trends and manipulate charts and tables; overlaying different forecasts within the one chart – using the comparison tool. Empower your business with our market intelligence centre, and receive alerts whenever your data is updated.

Interactive Excels (IFxl): Our IFxl tool enables clients to manipulate both forecast data and charts, within an Excel environment, to test their own assumptions using the interactive scenario tool and compare selected markets side by side in customised charts and tables. IFxls greatly increase a client’s ability to both understand a particular market and to integrate their own views into the model.

FORECAST SUMMARY

レポート構成＆価格表

Hampshire, UK – 10th October 2022: A new study from Juniper Research found that the number of ePharmacy users will reach 1 billion globally by 2027; increasing from 795 million in 2022, a growth of 28%. The research identified this increase as the culmination of surging adoption resulting from the COVID-19 pandemic, where consumers were unable to leave their homes and turned to receiving medication through ePharmacies. Growth will continue, as vendors focus on retaining and expanding their customer bases by refining the efficiency and simplicity that ePharmacy provides.

ePharmacy is where online pharmacies sell medication, including prescriptions, over the Internet, with the ability to deliver straight to the consumer.

Increase in Accessibility of eCommerce Driving Growth

The research predicts that consumers will continue to utilise ePharmacies as they realise the benefits they provide them, including affordability of medication, and a wider range of choice compared to bricks‑and-mortar pharmacies.

Furthermore, the report predicts that ePharmacy growth will be sustained by simplifying the online process. This can be achieved through more widespread acceptance of ePrescriptions; eliminating paper copies of prescriptions.

Research author Cara Malone remarked: “ePharmacy vendors have the ability to further simplify the process through the use of solutions, including consumers receiving their prescribed medication, sorted into daily pouches containing information regarding dosage, date and time to be taken.”

Issues Surrounding Delivery Remain a Barrier

The research anticipates that ePharmacy services will continue to be predominantly utilised for OTC (Over-the-Counter) medication. OTC transactions will reach 8.9 billion globally in 2027; accounting for 64% of total global transaction value. This is compared to 5 billion prescription transactions globally in the same year. Prescription digitisation will lag behind due to consumer concerns around delivery accuracy, timing and missed deliveries. In order to allay these concerns and offset the abundance of illegitimate ePharmacies, real-time tracking and stronger regulations for ePharmacies should be priorities to secure future growth.

Juniper Research provides research and analytical services to the global hi-tech communications sector; providing consultancy, analyst reports, and industry commentary.

目次

Contents

1. Key Takeaways & Strategic Recommendations

1.1 Key Takeaways & Strategic Recommendations ………6
1.2 Strategic Recommendations …………….7

2. Current Status & Future Outlook

2.1 Overview of ePharmacy Ecosystem ………….9
Figure 2.1: Visualisation Showing ePharmacy Stages ……..9
2.1.1 Types of ePharmacy…………….9
i. Digital-only Stores …………..9
ii. Digital Twin of Bricks-and-Mortar…………9
2.1.2 ePrescribing ……………..9
Figure 2.2: Visualisation of ePrescribing………… 10
2.2 Benefits of ePharmacy……………10
2.2.1 Benefits for Consumers…………..10
i. Time Saving ……………..10
ii. Cost Savings ………………10
iii. Efficiency……………..11
iv. Personalisation ……………11
v. Range of Choice……………11
2.2.2 Benefits for Corporations…………..11
i. Time Saving ……………..11
ii. Maximise Profit Margin…………11
Figure 2.3: Visualisation Showing Benefits for Corporates…… 12
iii. Benefits for Governments …………12
2.3 Exploration of Key Market Drivers…………..12
2.4 Limitations………………..13

3. Regional Analysis

3.1 Regional Analysis……………… 16
3.1.1 North America…………….. 16
i. US……………… 16
ii. Canada …………….. 16
3.1.2 Latin America ……………… 17
i. Mexico………………. 17
ii. Brazil……………… 17
3.1.3 West Europe…………….. 18
i. Germany ……………… 18
ii. UK……………….. 18
3.1.4 East & Central Europe ……………. 19
i. Poland ………………. 19
ii. Turkey………………. 19
3.1.5 Far East & China…………….. 20
i. China………………. 20
ii. South Korea ……………… 20
3.1.6 Indian Subcontinent……………. 20
i. India……………….. 20
ii. Pakistan……………. 21
3.1.7 Asia Pacific …………….. 21
i. Australia ……………. 21
ii. Philippines …………….. 21
3.1.8 Africa & Middle East ……………. 22
i. Egypt………………. 22
ii. United Arab Emirates ………….. 22

4. Competitor Leaderboard and Vendor Profiles

Table 4.1: Juniper Research Competitor Leaderboard: ePharmacy Vendors Included & Product Portfolio …………… 26
Figure 4.2: Juniper Research Leaderboard: ePharmacy Vendors …. 27
Table 4.3: Juniper Research Leaderboard: ePharmacy Vendors & Positioning .. 27
Table 4.4: Juniper Research Leaderboard Heatmap: ePharmacy Vendors … 28

4.1 ePharmacy – Vendor Profiles …………….29
4.1.1 1mg ………………..29
i. Corporate Information ………….29
ii. Geographical Spread…………….29
iii. Key Clients and Partnerships ………….29
iv. High-Level of Offerings …………..29
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..29
4.1.2 Amazon Pharmacy …………….30
i. Corporate Information ………….30
Table 4.5: Amazon’s Select Financial Information ($bn), FY2019-2021 (FYE 31st December)………………. 30
ii. Geographical Spread…………….30
iii. Key Clients and Partnerships ………….30
iv. High-Level of Offerings …………..30
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..30
4.1.3 Apollo Pharmacy …………….31
i. Corporate Information ………….31
ii. Geographical Spread…………….31
iii. Key Clients and Partnerships ………….31
iv. High-Level of Offerings …………..31
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..31
4.1.4 CVS Pharmacy………………32
i. Corporate Information…………. 32
Table 4.6: CVS Health Corporation’s Select Financial Information ($bn), FY 2019-2021 (FYE 31st December) ……………32
ii. Geographical Spread …………… 32
iii. Key Clients and Partnerships…………. 32
iv. High-level of Offerings………… 32
v. Juniper Research’s View: Key Strengths & Strategic Development
Opportunities ……………. 33
4.1.5 DocMorris ……………… 33
i. Corporate Information…………. 33
Table 4.7: Zur Rose’s Select Financial Information ($bn), FY 2019-2021 (FYE 31st December)………………..33
ii. Geographical Spread …………… 33
iii. Key Clients and Partnerships…………. 33
iv. High-Level View of Offerings……….. 33
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities ……………. 34
4.1.6 Express Scripts ……………. 34
i. Corporate Information…………. 34
ii. Geographical Spread …………… 34
iii. Key Clients and Partnerships…………. 34
iv. High-level of Offerings………… 35
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities ……………. 35
4.1.7 Giant Eagle…………….. 35
i. Corporate Information…………. 35
ii. Geographical Spread …………… 35
iii. Key Clients and Partnerships…………. 35
iv. High-Level of Offerings………….. 36
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities ……………. 36
4.1.8 Lloyds Pharmacy …………….36
i. Corporate Information ………….36
ii. Geographical Spread…………….36
iii. Key Clients and Partnerships ………….36
iv. High-level of Offerings …………36
Figure 4.8: Visualisation of Lloyds Direct App………… 37
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..37
4.1.9 Netmeds………………37
i. Corporate Information ………….37
ii. Geographical Spread…………….37
iii. Key Clients and Partnerships ………….37
iv. High-level of Offerings …………38
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..38
4.1.10 Optum ……………….38
i. Corporate Information ………….38
ii. Geographical Spread…………….38
iii. Key Clients and Partnerships ………….38
iv. High-Level of Offerings …………..38
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..39
4.1.11 Rowlands Pharmacy …………..39
i. Corporate Information ………….39
ii. Geographical Spread…………….39
iii. Key Clients and Partnerships ………….39
iv. High-Level of Offerings …………..39
Figure 4.9: Rowlands Pharmacy Hey Pharmacist……… 40
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..40
4.1.12 The Kroger ………………40
i. Corporate Information…………. 40
Table 4.10: Kroger’s Select Financial Information ($bn), FY2020-2022 (FYE 31st January)…………………40
ii. Geographical Spread …………… 40
iii. Key Clients and Partnerships…………. 41
iv. High-Level of Offerings………….. 41
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities ……………. 41
4.1.13 Walgreens Boots Alliance ………….. 41
i. Corporate Information…………. 41
Table 4.11: Walgreens Boots Alliance’s Select Financial Information ($bn),
FY2019-2021 (FYE 30th August) …………….42
ii. Geographical Spread …………… 42
iii. Key Clients and Partnerships…………. 42
iv. High-level of Offerings………… 42
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities ……………. 42
4.1.14 Walmart ……………. 42
i. Corporate Information…………. 42
Table 4.12: Walmart’s Select Financial Information ($bn), FY 2020-2022 (FYE 31st January)…………………43
ii. Geographical Spread …………… 43
iii. Key Clients and Partnerships…………. 43
iv. High-level of Offerings………… 43
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities ……………. 43
4.1.15 Well Pharmacy …………….. 43
i. Corporate Information…………. 43
ii. Geographical Spread …………… 44
iii. Key Clients and Partnerships…………. 44
iv. High-level of Offerings………… 44
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..44
Table 4.13: Juniper Research Competitor Leaderboard Scoring Criteria…. 46

5. Market Forecasts

5.1 Introduction………………48
5.1.1 ePharmacy Prescription Forecast Methodology ……48
5.1.2 ePharmacy OTC Forecast Methodology ……..48
Figure 5.1: ePharmacy Prescription Revenue Methodology ……. 49
Figure 5.2: ePharmacy OTC Revenue Methodology……… 50
5.1.3 Total ePharmacy Transactions ………..51
Figure & Table 5.3: Total ePharmacy Transactions (m), Split by 8 Key Regions, 2022-2027………………. 51
Table 5.4: Total ePharmacy Transactions, Split by Prescription and OTC Medication ………………… 51
5.1.4 Total ePharmacy Transaction Value…………52
Figure & Table 5.5: Total ePharmacy Transaction Value ($m), Split by 8 Key Regions, 2022-2027 ……………… 52
Table 5.6: Total ePharmacy Transaction Value, Split by Prescription and OTC Medication ………………… 52
5.1.5 Total ePharmacy Revenue………….54
Figure & Table 5.7: Total ePharmacy Revenue ($m), Split by 8 Key Regions, 2022-2027……………….. 54
Table 5.8: Total ePharmacy Revenue ($m), Split by Prescription and OTC Medication ………………… 54